Circio Holding ASA (OSL:CRNA)

Market Cap	58.93M
Revenue (ttm)	n/a
Net Income (ttm)	57.52M
Shares Out	94.74M
EPS (ttm)	2.79
PE Ratio	0.22
Forward PE	0.97
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,527,117
Average Volume	1,375,841
Open	0.5700
Previous Close	0.5700
Day's Range	0.5600 - 0.7500
52-Week Range	0.4800 - 13.2000
Beta	1.52
RSI	47.16
Earnings Date	Aug 28, 2025

About Circio Holding ASA

Circio Holding ASA, a biotechnology company, develops novel circular RNA and immunotherapy medicines. The company is developing TG01, a cancer vaccine targeting driver mutations, which is in three clinical trials for multiple myeloma, and pancreatic and lung cancer; and circVec circRNA vector platform, a modular genetic cassette for biogenesis of multifunctional circRNAs in human cells. It has a collaboration with Certest Biotec, S.L. for formulation of circVec. The company was formerly known as Targovax ASA and changed its name to Circio Holdi...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 10
• Stock Exchange: Oslo Børs
• Ticker Symbol: CRNA